2016 discharge: Innovative Medicines Initiative 2 (IMI)

This procedure concerns the 'discharge' process, which is the final approval of how the Innovative Medicines Initiative 2 (IMI 2) managed its budget for the 2016 financial year. It ensures that EU funds were used legally, efficiently, and for their intended purposes in developing new medicines.

This affects the management of the IMI 2 Joint Undertaking and the pharmaceutical research partners involved. A positive discharge confirms the organization's financial accountability to the European Parliament.